Keyphrases
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Androgen Deprivation Therapy
100%
Differential Use
100%
Confidence Interval
55%
Odds Ratio
55%
Race-ethnicity
44%
Neighborhood Socioeconomic Status
44%
Insurance
22%
Initial Treatment
22%
Non-Hispanic White
22%
Hispanic or Latino
22%
Medicaid
11%
Tumor
11%
Radiotherapy
11%
Chemotherapy
11%
Private Health Insurance
11%
Lymph Node Sampling
11%
Public Health Insurance
11%
Serum Testosterone
11%
Comorbidity
11%
Metastatic Disease
11%
Multivariable
11%
Social Factors
11%
Advanced Prostate Cancer
11%
Prostate-specific Antigen Level
11%
Quality of Life Impact
11%
Rural Areas
11%
Delayed Diagnosis
11%
Rural-urban
11%
Multivariable Model
11%
Veterans Affairs
11%
Military Veterans
11%
Asian Pacific Islander
11%
Insurance Status
11%
Area of Residence
11%
Year of Diagnosis
11%
Marital Status
11%
Location of Care
11%
Bilateral Orchiectomy
11%
California Cancer Registry
11%
Long-term Quality of Life
11%
Gleason Score
11%
Hispanic Origin
11%
Cumulative Costs
11%
Firth Logistic Regression
11%
Therapy Interruption
11%
Therapy Strategy
11%
Biochemistry, Genetics and Molecular Biology
Cancer Registry
100%
Treatment Interruption
100%
Gleason Score
100%
Testosterone Blood Level
100%
Prostate-Specific Antigen
100%
Comorbidity
100%
Medicine and Dentistry
Prostate Cancer
100%
Androgen Deprivation Therapy
100%
Odds Ratio
55%
Socioeconomic Status
44%
Health Care Cost
22%
Quality of Life
22%
Chemotherapy
11%
Neoplasm
11%
Flexibility
11%
Metastatic Carcinoma
11%
Radiation Therapy
11%
Cancer Registry
11%
Lymph Node
11%
Logistic Regression Analysis
11%
Veterans Affairs
11%
Identified Patient
11%
Orchiectomy
11%
Prostate Specific Antigen
11%
Gleason Score
11%
Marital Status
11%
Treatment Interruption
11%
Asian Pacific Islanders
11%
Comorbidity
11%
Immunology and Microbiology
Prostate Specific Antigen
100%
Gleason Score
100%
Testosterone Blood Level
100%
Lymph Node
100%
Comorbidity
100%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Androgen
100%
Chemotherapy
11%
Cancer Registry
11%
Metastasis
11%
Prostate Specific Antigen
11%
Gleason Score
11%
Neoplasm
11%
Comorbidity
11%